Ph.D., Principle Scientist, Bluestar Genomics
Biography
Dr. Anna Bergamaschi has extensive background in cancer biology and cancer genomic methods for the development of molecular diagnostic tests. At Genomic Health, Dr. Bergamaschi has been involved in numerous assay development efforts and led the technical development of a mutation based liquid biopsy test, aimed to identify actional mutations in late stage cancers. Since joining Bluestar Genomics in 2018, she has been leading the product development of the company’s first screening test.
Liquid Biopsy Showcase:
Bluestar Genomics
Founded out of the Stanford laboratory of Dr. Stephen Quake, Bluestar Genomics develops next-generation epigenomic approaches to non-invasive molecular testing to provide novel insight and quantification of human health and disease to improve healthcare outcomes.
Non-Invasive Epigenomic Methods For Detecting Multiple Cancers
Bluestar Genomics is developing a non-invasive assay using next-generation epigenomic technologies. From a simple blood test our technology, coupled with machine learning, enables the classification of multiple cancer types. Hear about our latest results from large cancer cohorts.
Session Abstract – PMWC 2020 Silicon Valley
Track 7 - January 23 9.00 A.M.-1.15 P.M.
The PMWC 2020 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).
